Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29088493 | 0.72 | — | — | |
| SCHEMBL2078459 | 0.72 | — | — | |
| SCHEMBL3281867 | 0.71 | — | — | |
| SCHEMBL1867115 | 0.71 | CA12 (0.38) | CA12CA14TAS1R3TAS1R1 | |
| SCHEMBL7720009 | 0.71 | SMN1; SMN2 (0.34) | CA12CA14 | |
| SCHEMBL4653372 | 0.69 | CA12 (0.54) | CA12CA14TAS1R3TAS1R1 | |
| SCHEMBL7724620 | 0.69 | SMN1; SMN2 (0.38) | CA12CA14 | |
| SCHEMBL1864255 | 0.69 | TSHR (0.30) | — | |
| SCHEMBL22370379 | 0.69 | BIRC2 (0.32) | CA12CA14 | |
| SCHEMBL22370381 | 0.69 | BIRC2 (0.32) | CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | CA12 789/4885CA14 733/4885TAS1R3 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.